Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GALR2 | O43603 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705335 | 0.90 | NAMPT (0.53) | NAMPTHDAC1NPC1RAB9AEGFR | |
| SCHEMBL10054867 | 0.90 | NAMPT (0.53) | NAMPTHDAC1NPC1RAB9AEGFR | |
| SCHEMBL2679487 | 0.88 | NAMPT (0.52) | NAMPTHDAC1 | |
| SCHEMBL10054865 | 0.88 | NAMPT (0.52) | NAMPTHDAC1 | |
| SCHEMBL10078169 | 0.85 | LMNA (0.54) | NAMPTHDAC1EGFRMMP1MMP2 | |
| SCHEMBL2679300 | 0.85 | LMNA (0.54) | NAMPTHDAC1EGFRMMP1MMP2 | |
| SCHEMBL10077752 | 0.84 | LMNA (0.64) | NAMPTHDAC1MEN1GALR2LMNA | |
| SCHEMBL2679317 | 0.84 | LMNA (0.64) | NAMPTHDAC1MEN1GALR2LMNA | |
| SCHEMBL10054789 | 0.84 | NAMPT (0.54) | NAMPTHDAC1NPC1RAB9AEGFR | |
| SCHEMBL2679216 | 0.83 | NAMPT (0.57) | NAMPTHDAC1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | NAMPT 3700/4885HDAC1 3479/4885NPC1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.